Literature DB >> 15699059

Inflammation stimulates remyelination in areas of chronic demyelination.

A K Foote1, W F Blakemore.   

Abstract

A major challenge in multiple sclerosis research is to understand the cause or causes of remyelination failure and to devise ways of ameliorating its consequences. This requires appropriate experimental models. Although there are many models of acute demyelination, at present there are few suitable models of chronic demyelination. The taiep rat is a myelin mutant that shows progressive myelin loss and, by 1 year of age, its CNS tissue has many features of chronic areas of demyelination in multiple sclerosis: chronically demyelinated axons present in an astrocytic environment in the absence of acute inflammation. Using the taiep rat and a combination of X-irradiation and cell transplantation, it has been possible to address a number of questions concerning remyelination failure in chronic multiple sclerosis lesions, such as whether chronically demyelinated axons have undergone changes that render them refractory to remyelination and why remyelination is absent when oligodendrocyte progenitor cells (OPCs) are present. Our experiments show that (i) transplanted OPCs will not populate OPC-containing areas of chronic demyelination; (ii) myelination competent OPCs can repopulate OPC-depleted chronically demyelinated astrocytosed tissue, but this repopulation does not result in remyelination--closely resembling the situation found in some multiple sclerosis plaques; and (iii) the induction of acute inflammation in this non-remyelinating situation results in remyelination. Thus, we can conclude that axonal changes induced by chronic demyelination are unlikely to contribute to remyelination failure in multiple sclerosis. Rather, remyelination fails either because OPCs fail to repopulate areas of demyelination or because if OPCs are present they are unable to generate remyelinating oligodendrocytes owing to the presence of inhibitory factors and/or a lack of the stimuli required to activate these cells to generate remyelinating oligodendrocytes. This non-remyelinating situation can be transformed to a remyelinating one by the induction of acute inflammation.

Entities:  

Mesh:

Year:  2005        PMID: 15699059     DOI: 10.1093/brain/awh417

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  71 in total

1.  Differential pathotropism of non-immortalized and immortalized human neural stem cell lines in a focal demyelination model.

Authors:  Daniela Ferrari; Cristina Zalfa; Laura Rota Nodari; Maurizio Gelati; Luigi Carlessi; Domenico Delia; Angelo Luigi Vescovi; Lidia De Filippis
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.

Authors:  Martin Stangel; Corinna Trebst
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

Review 3.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Authors:  Niels Bergsland; Eleonora Tavazzi; Ferdinand Schweser; Dejan Jakimovski; Jesper Hagemeier; Michael G Dwyer; Robert Zivadinov
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

5.  Neuroprotective effect of oligodendrocyte precursor cell transplantation in a long-term model of periventricular leukomalacia.

Authors:  Daniel J Webber; Marka van Blitterswijk; Siddharthan Chandran
Journal:  Am J Pathol       Date:  2009-10-22       Impact factor: 4.307

Review 6.  Immune influence on adult neural stem cell regulation and function.

Authors:  Pamela A Carpentier; Theo D Palmer
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

Review 7.  Cell therapy for multiple sclerosis.

Authors:  Tamir Ben-Hur
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

8.  Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia.

Authors:  Maria Karamita; Christopher Barnum; Wiebke Möbius; Malú G Tansey; David E Szymkowski; Hans Lassmann; Lesley Probert
Journal:  JCI Insight       Date:  2017-04-20

9.  Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair.

Authors:  Juan Carlos Biancotti; Shalini Kumar; Jean de Vellis
Journal:  Neurochem Res       Date:  2008-07-26       Impact factor: 3.996

10.  Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment.

Authors:  Kevin D Beck; Hal X Nguyen; Manuel D Galvan; Desirée L Salazar; Trent M Woodruff; Aileen J Anderson
Journal:  Brain       Date:  2010-01-19       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.